STING1 and neoplasm: Analyses revealed that the commercially available cGAS‐STING agonist ADU‐S100 and the small molecular tether 5BThi were relatively ineffective in inducing an IFN‐I response in tumor cells (Figure 2e; Figure S6, Supporting Information).